Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting mRNA Structure to Control Translation with Small Molecules

Project description

Messenger RNA as a target for therapy

Although most drugs work by binding to proteins, many disease-relevant proteins remain difficult or impossible to target directly. Messenger RNAs (mRNAs) – the molecular intermediates that carry instructions from DNA to produce proteins – represent a vast and largely unexplored alternative. Small molecules that bind to structured regions within mRNAs could modulate protein production without touching the protein itself. With the support of the Marie Skłodowska-Curie Actions programme, the TranStructRx project will develop a rational framework for identifying targetable structural motifs in disease-relevant mRNAs. This will also advance understanding of how the binding of small molecules translates into functional biological outcomes. The project aims to unlock the potential of mRNAs as a new class of drug targets and open therapeutic avenues for currently undruggable diseases.

Objective

mRNAs represent a vast and underexploited space for drug discovery. As direct regulators of protein synthesis, they provide a direct conduit to function. Current efforts to target RNAs in cells with small molecules often fail to robustly yield function in a predictable manner and usually need to be tailored on a target basis. A major reason is that most approaches prioritize binding affinity over biological outcome assuming, by analogy to proteins, that tighter binding necessarily induces greater efficacy. Yet for RNA, functional output depends more on structural context, temporal accessibility, and interaction dynamics than on affinity alone.
This proposal aims to discover structured, ligandable motifs in messenger RNAs (mRNAs) and to decode the mechanistic principles by which small-molecule binding can alter mRNA function. Because mRNAs control protein output directly, they offer a unique opportunity to modulate disease-relevant pathways, especially in cancers and intractable proteins. Recent unpublished work I conducted on targeting the ABL1 mRNA demonstrates this concept. We identified a functional structured element in the coding sequence of ABL1 through data-guided computational modeling. The motif we uncovered is responsive to small-molecule binding in cells. We aim to expand to other mRNAs and discover general, transferable routes to modulate translation via RNA structure.
Specifically, we will focus on three interconnected aims: (1) to discover functional, structured and targetable motifs in key mRNAs, (2) to understand how small-molecule binding can be transformed into biological function, (3) to elaborate a high-throughput screening platform to efficiently explore the functional RNA-ligand chemical landscape. Establishing a rational, generalizable framework for mRNA-targeted small molecules would open new therapeutic avenues, especially for currently undruggable and orphan disease targets.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

INSTITUT CURIE
Net EU contribution
€ 242 260,56
Address
RUE D ULM 26
75231 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)